- Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms
- Impression Healthcare is developing a drug it believes could treat acute respiratory distress syndrome associated with COVID-19 infection.
- Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress syndrome.
- If the effectiveness of IHL-675A in animal studies can be established, FDA consultants Camargo Pharmaceutical Services has advised Impression that IHL-675A will be a strong candidate for FDA Emergency Use Authorisation in treating COVID-19 symptoms.
Read full article: smallcaps.com.au